Boston Scientific (BSX) Current Deferred Revenue (2019 - 2020)
Boston Scientific's (BSX) quarterly Current Deferred Revenue came in at $147.0 million in Q3 2020, up 2.8% quarter-over-quarter from $143.0 million in Q2 2020.
Boston Scientific (BSX) Current Deferred Revenue (2019 - 2020) Analysis & Trends
Boston Scientific has disclosed Current Deferred Revenue across 2 years of filings, most recently posting $147.0 million for Q3 2020.
- Current Deferred Revenue for Q3 2020 came in at $147.0 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2020 was $147.0 million (changed N/A YoY), and the FY2019 annual result was $144.0 million, changed N/A from the prior year.
- Current Deferred Revenue came in at $147.0 million for Q3 2020 at Boston Scientific, up from $143.0 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $251.0 million in Q1 2020 to a low of $143.0 million in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn |
| 10 | Zimmer Biomet Holdings | 17.18 Bn | 16.77 Bn | 1.51 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 147.00 Mn |
| Jun 30, 2020 | 143.00 Mn |
| Mar 31, 2020 | 251.00 Mn |
| Dec 31, 2019 | 144.00 Mn |